腎臓がん治療薬の世界市場規模、シェア、成長分析、タイプ別、エンドユーザー別、流通チャネル別-産業予測、2023～2030年

腎臓がん治療薬の世界市場規模は2022年に44億米ドルと評価され、予測期間中（2024～2031年）のCAGRは5.50%で、2023年の46億4,000万米ドルから2031年には71億2,000万米ドルに成長する展望です。

近年の世界の腎臓がん治療薬市場は、医療研究の重点化と進歩により大きな変化を遂げています。標的療法と免疫療法の革新は腎臓がん治療薬の展望を再構築し、患者により効果的で低侵襲な選択肢を提供しています。腎臓がん治療薬に対する需要の増加は、早期発見に対する意識の高まりと努力によってもたらされています。医療機関と製薬企業の戦略的提携は、新規薬剤や治療アプローチの開発を促進しています。市場別では、病院とオフラインの薬局が引き続き優位を占めているもの、在宅医療とオンライン薬局のセグメントが大きく成長しています。現在、北米が最大の市場シェアを占めており、アジア太平洋が急速な成長を見せています。特筆すべき動向は、腎臓がん患者のQOL（生活の質）向上に重点を置いた、患者中心のケアの重要性が高まっていることです。市場開拓企業は、患者の転帰を向上させ、腎臓がん治療薬の未来を形作るという包括的な目標を掲げ、革新的な治療法を導入するための研究開発に多額の投資を行うことで、こうしたシフトに対応しています。

目次

エグゼクティブサマリー

• 市場概要
• 繁栄と衰退

調査手法

• 情報調達
• セカンダリとプライマリデータソース
• 市場規模の推定
• 市場の前提条件と制限

親市場の分析

• 市場概要
• 市場規模
• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題

主要市場の考察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 貿易分析
• スタートアップ分析
• 原材料の分析
• イノベーションマトリクス
• パイプライン製品の分析
• マクロ経済指標
• 主要投資の分析
• 主要成功要因
• 競合の程度

市場力学と展望

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• 規制情勢
• ポーターの分析
• 将来の混乱についての特別な考察

腎臓がん治療薬の世界市場：タイプ別

• 市場概要
• 腎細胞がん（RCC）
• 乳頭状腎細胞がん
• 嫌色素性腎細胞がん
• 未分類の腎細胞がん
• 移行上皮がん
• ウィルムス腫瘍（腎芽腫）
• 腎肉腫
• 血管筋脂肪腫
• 腫瘍細胞腫
• その他

腎臓がん治療の世界市場：エンドユーザー別

• 市場概要
• 病院
• 在宅医療
• 専門クリニック
• その他

腎臓がん治療薬の世界市場：流通チャネル別

• 市場概要
• 病院薬局
• オンライン薬局
• 小売薬局

腎臓がん治療薬の世界市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • その他の欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2021年）
• 主要市場企業が採用した戦略
• 主要成功戦略
• 市場における最近の活動
• 主要企業の市場シェア（2021年）

主要企業プロファイル

• Pfizer Inc（米国）
• Aurobindo Pharma（インド）
• Bristol-Myers Squibb Company（米国）
• Sanofi（フランス）
• Abbott（米国）
• Mylan N.V.（米国）
• Sun Pharmaceutical Industries Ltd（インド）
• F. Hoffmann-La Roche Ltd（スイス）
• Novartis AG（スイス）
• Takeda Pharmaceutical Company Limited（日本）
• Cipla Inc（インド）
• AstraZeneca（英国）
• Fresenius SE & Co. KGaA（ドイツ）
• Dr. Reddy's Laboratories Ltd（インド）
• Lupin（インド）
• Teva Pharmaceutical Industries Ltd（イスラエル）
• Endo International plc（アイルランド）

Global Kidney Cancer Drugs Market size was valued at USD 4.40 Billion in 2022 and is poised to grow from USD 4.64 Billion in 2023 to USD 7.12 Billion by 2031, at a CAGR of 5.50% during the forecast period (2024-2031).

Recent years have witnessed significant transformations in the global kidney cancer drugs market due to heightened focus and advancements in medical research. Innovations in targeted therapies and immunotherapies are reshaping the treatment landscape for kidney cancer, offering patients more effective and minimally invasive options. The increasing demand for kidney cancer treatments is driven by growing awareness and efforts in early detection. Strategic collaborations between healthcare institutions and pharmaceutical firms are fostering the development of novel drugs and treatment approaches. In terms of market segments, there has been substantial growth in the homecare and online pharmacy sectors, although hospitals and offline pharmacies continue to dominate. North America currently holds the largest market share, with the Asia-Pacific (APAC) region showing rapid growth rates. A notable trend is the growing importance of patient-centric care, with a strong focus on improving the quality of life for individuals with kidney cancer. Market players are responding to these shifts by investing heavily in research and development (R&D) to introduce innovative therapies, with the overarching goal of enhancing patient outcomes and shaping the future of kidney cancer treatment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Kidney Cancer Drugs and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global Kidney Cancer Drugs Market Segmental Analysis

The global kidney cancer drugs market is segmented on the basis of type, end user, distribution channel and region. Based on type the market is segmented as renal cell carcinoma (RCC), papillary renal cell carcinoma, chromophobe renal cell carcinoma, unclassified renal cell carcinoma, transitional cell carcinoma, Wilms tumor (Nephroblastoma), renal sarcoma, angiomyolipoma, oncocytoma, others. On the basis of End user, the market is segmented as hospitals, homecare, specialty clinics, others. Based on the distribution channel, it is segregated into hospital pharmacy, online pharmacy, and retail pharmacy. Regionally speaking, the market can be segmented into several categories, which are North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Kidney Cancer Drugs Market

Immunotherapy stands out as a significant catalyst in the expansion of the kidney cancer drugs market. This innovative approach harnesses the body's immune system to identify and combat cancer cells. With its ability to enhance the body's natural defences, immunotherapy has demonstrated promising results in kidney cancer treatment, particularly for cases where traditional therapies have been less effective. Ongoing research aimed at unveiling new combinations of treatments and immunotherapeutic agents is providing patients with access to less invasive and more efficacious alternatives, significantly improving their prospects in managing kidney cancer.

Restraints in the Global Kidney Cancer Drugs Market

One of the significant challenges in the kidney cancer drugs market is the presence of stringent regulatory barriers. While these regulations are crucial for ensuring patient safety and the effectiveness of drugs, they often result in prolonged approval timelines for new treatments. The extensive clinical trials and complex documentation required in the regulatory process contribute to delays in the availability of innovative therapies in the market. Furthermore, the varying regulatory landscapes across different regions add another layer of complexity for pharmaceutical companies seeking global approvals. These challenges collectively hinder the timely introduction of potentially life-saving drugs into the market, limiting treatment options for kidney cancer patients.

Market Trends of the Global Kidney Cancer Drugs Market

An important trend shaping the kidney cancer drugs market is the move towards personalized treatment strategies. This shift is driven by advancements in molecular diagnostics and genetic profiling, which enable the identification of specific biomarkers. These biomarkers facilitate the development of customized therapies tailored to individual patient characteristics. This trend represents a significant advancement in kidney cancer care, as it improves treatment efficacy while minimizing potential side effects.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Kidney Cancer Drugs Market by Type

• Market Overview
• Renal Cell Carcinoma (RCC)
• Papillary Renal Cell Carcinoma
• Chromophobe Renal Cell Carcinoma
• Unclassified Renal Cell Carcinoma
• Transitional Cell Carcinoma
• Wilms Tumor (Nephroblastoma)
• Renal Sarcoma
• Angiomyolipoma
• Oncocytoma
• Others

Global Kidney Cancer Drugs Market by End user

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Kidney Cancer Drugs Market by Distribution Channel

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Kidney Cancer Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Pfizer Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo International plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments